What changes technically when an ADC carries two payloads instead of one
M Peptides Supplier Reconstitute Peptides Two payloads do not mean two independent conjugations. In dual-payload design the controllable parameters are where each drug attaches, how each is released, the average total DAR and the A:B payload ratio, so DAR_total = DAR_A + DAR_B, with the A:B ratio as a separate controllable parameter (Wen et al., mAbs, 2025). A construct can hold total DAR constant and still be a different molecule.
The linker architecture carries that burden. Branched linkers with orthogonal reactive handles, for example one thiol-reactive and one click-reactive arm, allow sequential attachment of chemically incompatible payloads (Wen et al., mAbs, 2025). Published constructs show how wide the design space runs: a 2026 survey of dual-load constructs tabulates DAR pairs ranging from high-load anti-CD30 MMAE/MMAF conjugates down to low-load MMAF/SN38 pairs (Pharmaceuticals 19:860, 2026).
Ratio matters on its own. A 2025 review of homogeneous dual-payload conjugation methods reports a 4+2 MMAE/MMAF construct with superior efficacy to both a DAR6 MMAE ADC and co-administered DAR4 single-payload ADCs, in preclinical models from a group that sells a dual-payload platform (Wen et al., mAbs, 2025). Treat that as a design hypothesis, not a validated ratio. The practical consequence for ADC linker-payload chemistry is that the peptide and linker must be specified per arm, not per molecule.
Where the peptide fits, and why the linker-peptide is the hard part
That per-arm specification lands on the peptide, which must be synthesized to a specification before any conjugation happens and is where sequence-level failure modes surface. The Val-Cit-PABC linker family depends on lysosomal enzyme cleavage followed by a self-immolative PABC spacer that releases the payload by 1,4/1,6-elimination (Guo et al., Frontiers in Immunology, 2026). The GGFG tetrapeptide linker used in DXd conjugates is cleaved by the same lysosomal route, so the peptide sequence is doing release chemistry, not just spacing.
Dual-payload architectures push the peptide further. SPARC’s multipayload linker architecture builds modules from a dipeptide VA linker plus a polysarcosine-PAB self-immolative spacer, assembled by CuAAC and attached orthogonally at the VA site (Sun et al., Bioconjugate Chemistry, 2025). That is a peptide with a defined branching point, ib qho khoom tso tawm tshwj xeeb thiab ib qho chaw txuas thib ob tau teev tseg, tag nrho nyob hauv ib qho kev txiav txim.
Cov yam ntxwv ntawd kuj yog cov kev pheej hmoo ntawm kev tsim khoom. Ib qho kev sib txuas nqa ob lub cysteines tiv thaiv sib txawv, ib qho kev nthuav dav hydrophobic-ze ntawm cov khoom thauj thiab ib qho spacer uas ua rau nws tus kheej kub hlawv tsom rau cov teeb meem solid-phase classic: epimerization ntawm txhua qhov kev sib txuas, ua raws li partimide uas Asp-Gly motifs tshwm sim, thiab kev sib sau ntawm resin los ntawm hydrophobic khiav. Seattle Genetics orthogonal cysteine txoj kev qhia tias tshuaj lom neeg no ua tau ntawm ib qho protein folded (Levengood et al., Angew Chem Int Ed, 2017); seb ib tug neeg muab khoom tuaj yeem ua tau nws raws li koj qhov kev ntsuas yog ib lo lus nug sib txawv, thiab qhov uas txiav txim koj lub sijhawm.
How is a dual-handle linker-peptide synthesized and orthogonally protected?
Orthogonal protection tso cai rau staged functionalization thaum txhua reagent thiab intermediate ua tau raws kauj ruam tom ntej. The reference 2017 chemistry is a historical example, not the sole workable route; select a scalable process and control reagent residues, including metals where relevant.
The selectivity is the point. Protecting one cysteine as a reducible disulfide and another as Acm lets payloads be installed one after the other (Levengood et al., Angew Chem Int Ed, 2017). Acm is stable to TCEP but removed by aqueous mercury acetate, which is what makes the order possible (Levengood et al., Angew Chem Int Ed, 2017). The same paper reports the construct at 16 total drugs, split 8+8, at 98% monomer with antigen binding retained, which is why the deprotection order is a design constraint rather than a purification detail.
Sortase A commonly recognizes an LPXTG motif, of which LPETG is an example, and can ligate to an appropriate oligoglycine nucleophile. Motif and substrate requirements depend on the enzyme and construct.
How we apply this at MOL Changes, the publisher of this guide. We synthesize custom peptides to your specified sequence, mus txog 200 amino acids, so a linker-peptide can be built to the per-arm specification you set before conjugation. We do not perform orthogonal cysteine protection or any conjugation step, and we make no dual-payload linker claim; the protection scheme, conjugation route and DAR control remain yours to design and verify.
How does site-specific conjugation constrain peptide design?
The conjugation route decides which handles your peptide must carry and which must stay protected. Stochastic lysine or interchain-cysteine conjugation gives heterogeneous DARs, while engineered cysteine, non-canonical amino acid and glycan-remodelling routes give tighter DAR control, with glycan remodelling at Fc Asn297 using a structurally remote site that minimally perturbs antigen binding (Ocana et al., Signal Transduction and Targeted Therapy, 2026). Each route translates into a different peptide specification.
Published pipeline counts are date- and definition-dependent and differ between reviews. Entry into an early clinical study is not evidence Polypeptide Supplier of clinical benefit. This article does not establish a complete current count or a class-wide efficacy or safety conclusion.
The sources disagree on how much site-specific bioconjugation buys. One 2026 review states plainly that it remains unclear how much homogeneity improvements contribute to clinical outcomes, noting that trastuzumab emtansine, trastuzumab deruxtecan and sacituzumab govitecan all use conventional conjugation and show clinical benefit (Kumari et al., Cancers, 2026). Another frames site-specific methods as enabling tighter DAR control while preserving antibody structure and antigen affinity (Ocana et al., Signal Transduction and Targeted Therapy, 2026). Both can be true: tighter control is a quality attribute, and its clinical translation is unproven. No source quantifies what share of the pipeline uses site-specific versus random conjugation, so treat any such figure with suspicion.
How should purity be specified: peptide purity, conjugate purity, DAR distribution?
A single HPLC percentage is not a purity specification. The EMA synthetic-peptide guideline that took effect in June 2026 sets Ph. Eur. thresholds for peptide-related impurities at report above 0.1%, identify above 0.5% and qualify above 1.0%, requires any impurity method to at least meet the 0.1% reporting threshold, and does not recommend grouping of separable impurities (EMA/CHMP/CVMP/QWP/367182/2025, in effect 2026-06-01). It also treats purity as one of the most important CQAs for synthetic peptides and requires the active-substance specification to state total and individual impurities against those thresholds.
The method behind the number has its own requirements. ICH Q2(R2) validation expectations require purity and impurity method specificity to be demonstrated against spiked or stressed samples and by an orthogonal procedure where impurities cannot be isolated (ICH Q2(R2), 2023). One HPLC method, however well it runs, is not a validated purity claim.
Impurity classes are real, even where frequencies are not published. A 2026 impurity survey of follow-on synthetic semaglutide found 57 impurities above a 0.02% cut-off across nine drug substances, with deletions of Thr, His and Gly among the identified species (Kopp et al., Pharmaceutical Research, 2026). That supports “deletions occur and must be looked for”; it does not support a deletion rate.
The scope limit matters. The EMA guideline addresses conjugation moieties and linkers as CMC topics, including supplier documentation and mutagenic-impurity assessment, and says nothing about ADCs, dual payloads or DAR. Use it for the peptide, not for the conjugate.
Define peptide and linker identity, relevant impurities, conjugate species, total and per-payload loading, free payload and stability for the actual construct. SEC alone does not establish overall conjugate purity; combine methods with demonstrated coverage. Synthetic-peptide thresholds are not automatically ADC-linker acceptance limits.
What belongs in the analytical handoff package from discovery to development?
The handoff package has to let the receiving team reproduce your numbers without redeveloping the assays. For multi-payload ADCs the bioanalytical strategy must extend beyond total antibody to conjugated-antibody assays, conjugated-payload LC-MS and intact-mass work, with middle-down analysis for mean drug load distribution (Riccardi Sirtori et al., Bioanalysis, 2025). Kev tshuaj xyuas nruab nrab rau kev faib tshuaj nruab nrab yog qhov feem ntau ploj ntawm pob kev tshawb nrhiav.
Tus neeg muab peptide pab yog me dua tab sis muaj tseeb. Yuav ua li cas tus neeg muab linker-peptide txhais QC haum rau hom phiaj yog HPLC lossis UPLC purity ntxiv LC-MS tus kheej, nrog kev xaiv ua ntej- thiab tom qab kev txiav tawm (Bio-Synthesis, cleavable peptide linkers, tau txais rov qab 2026-10). Thov cov chromatograms thiab mass spectra tshwj xeeb rau lot, tsis yog daim ntawv pov thawj.
Ob qhov chaw tsis muaj tseeb. Tsis muaj qhov chaw piav qhia txog txoj kev tswj hwm uas tau lees paub rau kev ntsuas DAR ntawm txhua payload hauv cov qauv kuaj mob, thiab RPLC-UV txo qis feem ntau tsis tuaj yeem daws tau tus nqi DAR ib leeg rau txhua payload vim tias cov saw hnyav uas muaj DAR tag nrho zoo ib yam tab sis muaj kev teeb tsa payload sib xyaw ua ke (Pharmaceuticals 19:860, 2026). ICH Q6B’s specification framework provides the general principles for setting and justifying specifications for biological products (FDA, Q6B, 1999), but the framework does not tell you which assay resolves your two payloads.
Handoff checklist: sequence and lot number; protecting-group scheme and deprotection order; HPLC/UPLC method with column, v; LC-MS identity with observed versus theoretical mass; impurity table against 0.1/0.5/1.0%; cleavage verification if the linker is enzyme-cleavable; and a stated method for per-payload DAR, or an explicit note that it is unresolved.
How do you choose between a flexible specialist and a fully integrated provider?
The choice turns on where your constraint actually sits. An integrated provider offers one contract across antibody, linker, payload and fill-finish; Lonza’s integrated ADC manufacturing model describes gram-scale payload production and multi-kilogram capacity at Visp with an integrated offer across antibodies, linkers, payloads, bioconjugation and sterile fill-finish (Lonza, Purity Peptides tau txais rov qab 2026-10). Its phase-appropriate Advanced Synthesis model stages capabilities across discovery, development and clinical supply rather than offering everything at every stage (Lonza media advisory, 2026). Peptide Factory Factory
A specialist concentrates on one layer. That is an advantage when the hard problem is a sequence: two differentially protected cysteines, a polysarcosine spacer, an LPETG tag or a hydrophobic run that aggregates on resin. It is a disadvantage when you need the same quality system to cover conjugation and fill-finish.
|
Criterion |
Flexible specialist |
Fully integrated provider |
|---|---|---|
|
Best fit |
Complex or branched peptide, txoj kev tiv thaiv txawv txav, kev rov ua sai sai |
Program uas xav tau ib qho system zoo los ntawm linker mus rau fill-finish |
|
Analytical tob Peptides Production |
Lot-level HPLC/MS thiab cleavage verification, kev tsim txoj kev rau peptide |
Platform assays thoob plaws conjugate, payload thiab qhov hnyav tag nrho |
|
Kev pheej hmoo nce qib |
Kev hloov mus rau qhov chaw thib ob rau conjugation thiab kev muab tshuaj kho mob |
Kev hloov chaw ib leeg, tsawg kev poob ntawm kev hloov chaw |
|
Qhov twg yuav probe |
Kev paub tiv thaiv orthogonal, per-payload DAR txoj kev, impurity reports 0.1% |
Yog peptide txheej tau txais txoj kev tsim tshwj xeeb lossis platform default |
Kev sib piv yog kev xav ntawm editorial, tsis yog kev txheeb xyuas qhov chaw; tsis muaj qhov chaw kuv tshuaj xyuas benchmark ob qho qauv sib tw ncaj qha. Siv nws los tsim cov lus nug, tom qab ntawd cia cov lus teb txiav txim.
Caveats
Ob qho kev ceeb toom chemistry. Cov orthogonal cysteine conditions los ntawm 2017 and were demonstrated on a model antibody, so they are a design reference, not a validated process (Levengood et al., Angew Chem Int Ed, 2017). And the claim that high DAR causes aggregation has a documented exception: the 8+8 construct reached 98% monomer with a PEG24 stretcher, so hydrophobicity masking, not DAR alone, is the variable. No source provides a measured yield or purity loss for scaling a complex modified peptide from milligram to kilogram; that risk stays qualitative.
Cov Lus Nug Nquag Nug
Does high DAR always cause aggregation and fast clearance?
PM. High DAR is associated with aggregation and accelerated clearance for hydrophobic payloads, but the relationship is modulated by linker hydrophobicity (Ocana et al., Signal Transduction and Targeted Therapy, 2026). A dual-auristatin construct with a PEG24 stretcher reached 98% monomer (Levengood et al., Angew Chem Int Ed, 2017).
Does the EMA synthetic-peptide guideline cover dual-payload ADCs?
PM. It covers synthetic peptides and treats conjugation moieties and linkers as CMC topics; it says nothing about ADCs, dual payloads or DAR (EMA/CHMP/CVMP/QWP/367182/2025, in effect 2026-06-01).
Can a peptide specialist hand off to a clinical-stage provider?
Yog, if the handoff package carries lot-specific HPLC and LC-MS data, txoj kev pab pawg tiv thaiv thiab kev txiav txim tshem tawm kev tiv thaiv, and a stated method for per-payload DAR. Qhov chaw uas yuav npaj yog tias tsis muaj txoj kev tswj hwm uas tau lees paub rau per-payload DAR hauv cov qauv kuaj mob tau piav qhia hauv cov ntaub ntawv tau tshuaj xyuas (Pharmaceuticals 19:860, 2026).
Xaus lus
Txoj cai txiav txim rau tus khub txhawb nqa yog raws li ntawd. Txuas tus khub rau koj qhov kev txwv tiag tiag. Yog tias qhov kev txwv yog ib qho kev faib tawm lossis kev tiv thaiv sib txawv, ib tug kws tshaj lij uas muaj kev paub txog kev tiv thaiv orthogonal thiab kev tshuaj xyuas qib lot-level yog qhov haum dua. Yog tias qhov kev txwv yog ib qho system zoo ib leeg thoob plaws kev sib txuas thiab kev muab khoom kho mob, ib tug kws kho mob sib koom ua ke yeej hauv kev pheej hmoo hloov. Ob qho xwm txheej, thov pob tshuaj ntsuam ua ntej muab nqi, thiab saib tus neeg muab khoom uas tsis tuaj yeem piav qhia per-payload DAR ua ib tug neeg muab khoom uas tsis tau daws qhov teeb meem tshuaj ntsuam.
The next step is a technical review of your sequence and specification: protecting-group scheme, deprotection order, impurity thresholds and the DAR method, mapped against what a support partner can document lot by lot.
Publisher disclosure: MOL Changes supplies peptide services and has a commercial interest in this topic. Cov kev pabcuam thiab cov lus qhia txog peev xwm yog cov lus thov ntawm cov neeg muab khoom; Kev muaj thiab kev ua tau zoo rau ib qho qauv tshwj xeeb yuav tsum muaj pov thawj tshwj xeeb rau qhov project.
